Vertex Pharmaceuticals, Inc. (VRTX)
542.62
-4.41
(-0.81%)
USD |
NASDAQ |
Nov 12, 16:00
543.51
+0.89
(+0.16%)
After-Hours: 07:32
Vertex Pharmaceuticals Shareholders Equity (Quarterly) : 20.91B for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 20.91B |
| June 30, 2026 | 20.25B |
| March 31, 2026 | 19.36B |
| December 31, 2025 | 18.67B |
| September 30, 2025 | 17.32B |
| June 30, 2025 | 17.18B |
| March 31, 2025 | 16.50B |
| December 31, 2024 | 16.41B |
| September 30, 2024 | 15.63B |
| June 30, 2024 | 14.77B |
| March 31, 2024 | 18.55B |
| December 31, 2023 | 17.58B |
| September 30, 2023 | 16.51B |
| June 30, 2023 | 15.47B |
| March 31, 2023 | 14.43B |
| December 31, 2022 | 13.91B |
| September 30, 2022 | 13.03B |
| June 30, 2022 | 11.93B |
| March 31, 2022 | 10.91B |
| December 31, 2021 | 10.10B |
| September 30, 2021 | 9.531B |
| June 30, 2021 | 9.196B |
| March 31, 2021 | 8.980B |
| December 31, 2020 | 8.687B |
| September 30, 2020 | 8.133B |
| Date | Value |
|---|---|
| June 30, 2020 | 7.519B |
| March 31, 2020 | 6.462B |
| December 31, 2019 | 6.085B |
| September 30, 2019 | 5.253B |
| June 30, 2019 | 5.070B |
| March 31, 2019 | 4.723B |
| December 31, 2018 | 4.435B |
| September 30, 2018 | 2.906B |
| June 30, 2018 | 2.686B |
| March 31, 2018 | 2.401B |
| December 31, 2017 | 2.029B |
| September 30, 2017 | 1.791B |
| June 30, 2017 | 1.671B |
| March 31, 2017 | 1.500B |
| December 31, 2016 | 1.157B |
| September 30, 2016 | 1.022B |
| June 30, 2016 | 981.35M |
| March 31, 2016 | 957.08M |
| December 31, 2015 | 939.97M |
| September 30, 2015 | 922.15M |
| June 30, 2015 | 894.96M |
| March 31, 2015 | 976.46M |
| December 31, 2014 | 1.075B |
| September 30, 2014 | 1.156B |
| June 30, 2014 | 1.172B |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 3.604B |
| Gilead Sciences, Inc. | 13.04B |
| Regeneron Pharmaceuticals, Inc. | 33.50B |
| Sionna Therapeutics, Inc. | 240.52M |
| Amgen, Inc. | 14.35B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 32.74B |
| Total Liabilities (Quarterly) | 11.83B |
| Debt to Equity Ratio | 0.3099 |
| Current Ratio | 2.337 |
| Net Debt Paydown Yield | -0.75% |